Intercept Pharmaceuticals Inc  

(Public, NASDAQ:ICPT)   Watch this stock  
Find more results for ICPT
67.06
0.00 (0.00%)
Oct 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 54.98 - 142.10
Open     -
Vol / Avg. 0.00/2.64M
Mkt cap 1.68B
P/E     -
Div/yield     -
EPS -15.49
Shares 25.10M
Beta -2.10
Inst. own 88%
Nov 1, 2017
Q3 2017 Intercept Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 25, 2017
Intercept Pharmaceuticals Statement Regarding Ocaliva� Safety and Dosing in Primary Biliary Cholangitis (PBC) Patients - Call - Webcast
Sep 12, 2017
Intercept Pharmaceuticals Inc at Morgan Stanley Healthcare Conference - Webcast
Sep 6, 2017
Intercept Pharmaceuticals Inc at Robert W Baird Gobal Healthcare Conference - Webcast
Aug 16, 2017
Intercept Pharmaceuticals Inc at Wedbush PacGrow Healthcare Conference - Webcast
Jul 31, 2017
Q2 2017 Intercept Pharmaceuticals Inc Earnings Release
Jul 31, 2017
Q2 2017 Intercept Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -280.26% -1654.56%
Operating margin -260.66% -1613.31%
EBITD margin - -1417.61%
Return on average assets -54.09% -59.19%
Return on average equity -169.39% -90.03%
Employees 456 -
CDP Score - -

Address

10 Hudson Yards Fl 37
NEW YORK, NY 10001-2160
United States - Map
+1-646-7471000 (Phone)
+1-646-7471001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Officers and directors

Paolo Fundaro Independent Chairman of the Board
Age: 43
Bio & Compensation  - Reuters
Mark Pruzanski M.D. President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Sandip S. Kapadia Chief Financial Officer, Treasurer
Age: 47
Bio & Compensation  - Reuters
Lisa Bright President, International
Age: 49
Bio & Compensation  - Reuters
Jerome Benedict Durso Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
David Ford Chief Human Resource Officer
Bio & Compensation  - Reuters
Richard Kim Senior Vice President, Commercial U.S.
Age: 48
Bio & Compensation  - Reuters
Rachel L. McMinn Ph.D. Chief Business and Strategy Officer
Age: 44
Bio & Compensation  - Reuters
David M. Shapiro M.D. Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D. Ph.D. Independent Director
Age: 49
Bio & Compensation  - Reuters